NCT03463460 is a Phase 2 clinical trial of Laboratory Biomarker Analysis in Thymic Carcinoma, sponsored by Dwight Owen.

Who is sponsoring NCT03463460?

NCT03463460 is sponsored by Dwight Owen.

What drugs are being tested in NCT03463460?

Interventions in NCT03463460: Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate.

What condition does NCT03463460 study?

NCT03463460 studies Thymic Carcinoma.

Is NCT03463460 still recruiting?

NCT03463460 is currently active, enrolled. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT03463460

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Active, enrolled Phase 2 Last updated 23 March 2026

What this trial tests

Phase 2 trial testing Laboratory Biomarker Analysis in Thymic Carcinoma in 9 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 June 2018

Primary endpoint
30 April 2027

30 April 2027

Quick facts

Lead sponsor	Dwight Owen
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	19 June 2018
Primary completion	30 April 2027
Estimated completion	30 April 2027
Sites	3 locations across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Sunitinib Malate (sunitinib-malate) — full drug profile →

Conditions studied

Thymic Carcinoma — all drugs for Thymic Carcinoma →

Sponsor

Dwight Owen — full company profile →

Who can join

18 and older, any sex, with Thymic Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and sunitinib malate may work better in treating thymic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other recruiting trials for Thymic Carcinoma

Currently open trials in the same condition.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT06402708 — Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) · Phase 3 · recruiting
NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
NCT03076554 — A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma · Phase 2 · active not recruiting
NCT05667948 — Molecular Analysis and Treatment Options of Thymic Malignancies · recruiting

Other Dwight Owen trials

Trials by the same sponsor.

NCT06616623 — Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer · Phase 1 · recruiting
NCT05234307 — PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer · Phase 1 · recruiting
NCT04919382 — Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer · Phase 2 · recruiting
NCT04919369 — All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer · Phase 1 · active not recruiting
NCT03728361 — Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroend · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03463460 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dwight Owen
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03463460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing